Thomas Patrick Kelly - 15 Oct 2025 Form 4 Insider Report for Xenon Pharmaceuticals Inc. (XENE)

Reporting relationship: Chief Financial Officer
Issuer ticker: XENE
Reported as of: 15 Oct 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 17 Oct 2025, 18:43:47 UTC
Prior SEC filing: 11 Jun 2024
Source filing: View source filing
Reporting owner signature: /s/ Nathaniel Adams, Attorney-in-fact

Key filing fact

Thomas Patrick Kelly filed Form 4 for Xenon Pharmaceuticals Inc. (XENE) on 17 Oct 2025.

Key facts

This page summarizes Thomas Patrick Kelly's Form 4 filing for Xenon Pharmaceuticals Inc. (XENE).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 17 Oct 2025, 18:43.

Change

Previous filing in this sequence was filed on 11 Jun 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001410514 Primary reporting owner

Kelly Thomas Patrick

Relationship: Chief Financial Officer
Address: 3650 GILMORE WAY, BURNABY, BRITISH COLUMBIA, CANADA
Signature: /s/ Nathaniel Adams, Attorney-in-fact
Signature date: 17 Oct 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

XENE transaction Derivative

Share Option (Right to Buy)

Award

Transaction value: $0
Shares: +225,000
Change %
Price: $0.000000
Shares after: 225,000
Date: 15 Oct 2025
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 225,000
Exercise price: $41.90
Footnotes: F1

XENE transaction Derivative

Restricted Share Units

Award

Transaction value: $0
Shares: +30,000
Change %
Price: $0.000000
Shares after: 30,000
Date: 15 Oct 2025
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 30,000
Exercise price: $0.000000
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Vesting 25% on October 15, 2026, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month.

Footnote F2

Each restricted share unit represents a contingent right to receive one Common Share vesting 25% on each of the first four anniversaries of the date of grant, beginning on October 15, 2026.